por
Gus Iversen, Editor in Chief | June 01, 2026
TerraPower Isotopes and Belgian radioisotope producer PanTera have expanded their collaboration to increase global supplies of actinium-225 (Ac-225), a radioisotope being used in the development of targeted alpha therapies for cancer.
Under the agreement, the Fleurus, Belgium-based Institut des Radioéléments (IRE) will host and operate a new Ac-225 production line for PanTera, while TerraPower Isotopes will provide additional starting material to support expanded manufacturing, the companies said.
The move builds on an existing production program in Mol, Belgium, where PanTera is already supplying Ac-225 to drug developers. The companies said the expansion will support two initiatives: increasing weekly output at the Mol facility and establishing a second production site at IRE's facilities in Fleurus.
Ad Statistics
Times Displayed: 17108
Times Visited: 38 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
According to the companies, the combined effort is expected to increase PanTera's current Good Manufacturing Practices-compliant Ac-225 production capacity by more than 200%. The additional capacity is intended to support later-stage clinical trials and early commercial radiopharmaceutical programs.
“The demand from clients for dependable cGMP-compliant Ac-225 is outpacing projections and needs to be robust against interruptions in the production,” said Christophe Malice, chief business officer at PanTera, in a statement. He added that operating production across two sites in Belgium is intended to improve supply resilience while maintaining a single regulatory framework for customers.
The new production line at IRE is expected to become operational within 18 months.
The announcement comes as demand for Ac-225 continues to grow across the radiopharmaceutical sector. The isotope is considered a key component in targeted alpha therapies, an emerging class of cancer treatments designed to deliver radiation directly to tumor cells while limiting exposure to surrounding tissue.
Both companies are also investing in additional manufacturing capacity. TerraPower Isotopes, based in Bellevue, Washington, is expanding its Everett, Washington, laboratory and building a new cGMP facility in Philadelphia. PanTera is constructing a photonuclear production plant in Mol that is expected to support larger-scale Ac-225 production later this decade.
